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mmHg for liraglutide versus 130.1 (130.0, 130.1)/75.4 (75.4, 75.5) mmHg and 130.1
(129.0, 131.2)/75.5 (74.8, 76.1) mmHg for all comparison patients and per bootstrap,
respectively (p0.05 except bootstrap diastolic BP p0.05). CONCLUSIONS: A boot-
strap analysis provided more robust variance and 95% CI estimates for a large
comparison group. This technique can help researchers avoid identifying statisti-
cal significance when differences are not clinically meaningful when evaluating a
large patient cohort.
PODIUM SESSION III:
EVOLVING CONCEPTS IN OUTCOMES RESEARCH
EV1
DEVELOPMENT OF A GUIDANCE FOR INCLUDING PATIENT-REPORTED
OUTCOMES (PROS) IN POST-APPROVAL CLINICAL TRIALS OF ONCOLOGY
DRUGS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)
Basch EM1, Abernethy A2, Mullins CD3, Tiglao MR4, Tunis SR4
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 2Duke University Medical Center,
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OBJECTIVES:Although an FDAGuidance is available to direct the development and
inclusion of PROs in preapproval clinical research towards drug approval and la-
beling, no such guidance exists in the post-market CER context. Because the clin-
ical setting and stakeholders in CER differ from the preapproval space, different
methodological and practical considerations are necessary. The aim of this project
is to develop specific recommendations for capturing the patient perspective in
post-market oncology trials and other studies that fall into the general category
termed CER. METHODS: A semi-structured questionnaire pertaining to the use of
PROs in CER was developed based on a review of scientific literature and consulta-
tion with PRO study methodologists. In-depth interviews were conducted using
these questions with 15 individuals from the clinical research, clinical practice,
regulatory, payer, and patient communities. Based on interview responses, a list of
potential guidance topicswas developed. The Center forMedical Technology Policy
convened a multidisciplinary working group of leading medical researchers in
PROs, ePRO consultants, and patient advocates to discuss these topics and develop
an on outline of best practice recommendations for integrating PROs in CER.
RESULTS: A series of recommendations focused on establishing standards for the
use of PROs in CER were developed. These recommendations address selection of
appropriate measures; inclusion of a ”core minimum item set” across all oncology
CER trials; and inclusion of items which assess symptoms, global QOL, perceived
value of care, and treatment compliance. The recommendations also provide guid-
ance for how to implement PROs in real-world studies andminimize missing data.
CONCLUSIONS: The patient perspective is an essential component of CER. PRO
methods used in CER differ from the preapproval context. For improved consis-
tency across trials, a guidance is being developed which identifies a standard core
item set to be considered for use across all oncology CER studies.
EV2
PAYERS AND PROS: BEYOND QOL
Miller KL, Stevens CA
PAREXEL Consulting, Waltham, MA, USA
At the 2010 ISPOR conference medical directors from US health and pharmacy
plans provided their perspective on the value of health outcomes research in de-
ciding drug coverage. The message to the ISPOR members was that quality of life
holds little sway among these decision-makers. Nevertheless health care research-
ers, policy makers, legislators, and other stakeholders continue to emphasize the
inclusion of the patient perspective in comparative effectiveness research (CER)
and in health care decision making. Recently, in arguing the importance of patient
reported outcomes (PROs) in CER, Wu, et al. emphasize that interventions must
“improv[e] outcomes, reduc[e] costs, or both”. Indeed, as these authors state “many
relevant outcomes require patient-reported information”. So if QOL measures
aren’t the answer, which PROs will provide both the patient perspective and infor-
mation critical to decision makers in the private and public sectors? Collaboration
between payers and researchers will be essential to answer this question. How-
ever, the onus will fall squarely upon the health outcomes researchers, to identify
and quantify the relationship between outcomes and value. Furthermore, these
researchers will have to demonstrate the importance to the individual payers, as
they have little incentive to further complicate drug coverage decision making.
Therefore, even if improved outcomes - as measured by PROs - prove to provide
meaningful benefit to patients, payers will require that the information be appli-
cable specifically to their populations. For instance Wu, et al. suggest functional
status 90 days after discharge as an example of a relevant patient outcome. We, as
health outcomes researchers understand the relevance to patients; but for payers
we must answer how is improved functional status a valuable measure to individ-
ual payers?Without the answer to this type of question, payers will be reluctant to
include these outcomes endpoints in their decision making.
EV3
A COMPARATIVE EFFECTIVENESS INDEX TO INFORM CLINICAL DECISIONS
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OBJECTIVES: Present a framework to systematically measure and combine key
attributes of health interventions into a single Comparative Effectiveness Index
(CEI).METHODS: Relevant attributes including efficacy/effectiveness, compliance/
persistency, safety, health-related quality of life (HRQoL)/utility are linked through
a transparent formula. Efficacy and effectiveness are gathered from a meta-anal-
ysis of randomized controlled trials and observational studies, accordingly. Com-
pliance and persistency are be derived from pharmacy claims data using metrics
such as the medication possession ratio. We propose a 5-point rating scale for the
safety measure from low risk “suitable for widespread use” to high risk “careful
consideration of risk versus benefit”. We also consider a combined measure of
risk-benefit assessment borrowing from existing quantitative methods such as a
Number Needed to Treat and Number Needed to Harm. Generic or disease-specific
patient-reported outcome measures provide information on the impact of the in-
tervention on the patient’s HRQoL and indicate the value of a specific treatment for
a given health state. To ensure relevant comparisons, we account for therapeutic
areawhen assessing the CEI ofmultiple interventions. Finally, ameasure of quality
of evidence (Jadad score) ensure that only evidence from robust designs fed the CEI.
CONCLUSION: The CEI aims to provide a comprehensive and balanced picture of
disparate yet linked performance attributes. Currently, a complete picture of
health interventions is not centralized and not easily accessible thus limiting in-
formed clinical decision-making by various stakeholders (physicians, patients,
payers and policy makers). This index is intended to guide healthcare participants
in making evidence-based clinical decisions at the population and patient levels
such that a providermight want to trade-off effectiveness for increase safety when
treating a patient with severe comorbidities. For full transparency and use, we
propose the creation of a US publically available web-based database of the infor-
mation underlying the index.
EV4
MORE BANG FOR YOUR BUCK: TAKE A RISK WHEN ANALYSING INTERVIEW
DATA
Roberts G
Double Helix Consulting, London, UK
ISSUE: Data obtained by interview or questionnaire are routinely reported with
summary statistics, frequency, mean and range. Can we obtain more informative
results by interpreting the data using risk analysis techniques? OVERVIEW: Prob-
abilisticmethods can beusedwhendata is sparse and address areas of uncertainty.
Quantitative analysis of interview or questionnaire data typically involves present-
ing frequencies of response and summaries of aggregate data with descriptive
statistics. These are used often to address research questions including assessing
market access opportunities, pricing and reimbursement scenarios, filling gaps in
health economic data such as resource use. But dowe always get themost from the
data we have? How can we make better informed decisions? Let us consider a
hypothetical questionwhere respondents are asked to rate a series of attributes (A,
B, C) using a scale of 1 to 10. We end up with a distribution of answers that are
summarised as averages for each attribute. Oftenwe are then facedwith interpret-
ing a series of average scores that do not differ markedly between attributes. Un-
certainty in the ratings provided by respondents can be used to improve our inter-
pretation. One method would be to use bootstrap techniques, to sample with
replacement the raw data, and running a simulation to obtain the bootstrap un-
certainty distribution for the mean. From this we can determine the probability
that attribute A is better or worse than B or C.With this information at our disposal
we are better positioned to make an informed decision. CONCLUSION: Decision
analytic methods add value, improve communication about risk, support decision
making, and identify research opportunities for reducing uncertainty when inter-
preting interview and questionnaire data.
PODIUM SESSION III:
ANALYSIS OF MEDICARE POLICY AND RESOURCE USE
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USING COST-EFFECTIVENESS INFORMATION TO ALLOCATE MEDICARE
RESOURCES – HOW MUCH MORE HEALTH FOR THE MONEY?
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OBJECTIVES: The Centers for Medicare and Medicaid Services (CMS) do not explic-
itly use cost-effectiveness information in national coverage determinations
(NCDs). The objective of this studywas to estimate potential gains in health attain-
able from reallocating resources using cost-effectiveness information within the
existing level of spending, and to determine the consequences for the distribution
of resources.METHODS:NCDs from 1999 through 2007were included. Estimates of
the cost-effectiveness of included coverage decisions, both positive and non-cov-
erage, were identified from a literature review. For coverage decisions with an
associated estimate of cost-effectiveness (n66), an estimate of utilization and size
of the ‘unserved’ eligible patient population was established from a Medicare 5%
claims database (2007) using a combination of diagnostic (ICD-9) and reimburse-
ment (CPT) codes. Annual and net costs were taken from the cost-effectiveness
study or estimated using reimbursement codes. RESULTS: Complete information
was available for 36 (55%) coverage decisions with an associated estimate of cost-
effectiveness. A reallocation of resources yielded an increase in aggregate quality
adjusted life years (QALYs) of 1.8 million, approximately 0.15 QALYs per Medicare
beneficiary affected by the reallocation. The analysis provides a quantification of
how the reallocation affected different patient populations and the utilization of
different types of technology. In summary, following reallocation, a greater pro-
portion of resources were directed to oncology, diagnostic imaging and tests, and
diseases affecting 1 million Medicare beneficiaries, than prior to reallocation.
Conversely, following reallocation, a decreased proportion of resources were di-
rected to cardiology, interventions other than diagnostic tests, and diseases affect-
ing 50k-1millionMedicare beneficiaries, than prior to reallocation.CONCLUSIONS:
Using cost-effectiveness information to inform CMS NCDs has the potential to sub-
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stantially increase the aggregate health ofMedicare beneficiarieswhile not increasing
Medicare spending. The reallocation resulted in a greater proportion of resources di-
rected towards diagnostics tests, more prevalent diseases, and oncology.
MD2
PRESCRIPTION DRUG COST AND USE IN THE MEDICARE PART D
POPULATION - USES OF A NEW LIMITED DATA SET
Powers CA1, Varghese A1, Hsu VD2, O’Donnell J3, Schneider K3
1Centers for Medicare & Medicaid Services (CMS), Baltimore, MD, USA, 2Buccaneer, A Vangent
Company, Owings Mills, MD, USA, 3Buccaneer, A Vangent Company, West Des Moines, IA, USA
OBJECTIVES:While Medicare Part D research identifiable files have been available
to academic researchers for some time, a new limited data set (LDS) containing Part
D drug utilization and cost information is now available to both academic and
non-academic researchers. This study was undertaken to demonstrate the versa-
tility of LDS in analyzing drug utilization and cost.METHODS: Aged Medicare ben-
eficiaries alive for all of 2008 with 12 months of Part A, B, and D coverage were
selected. The average number of prescription drug fills (30-day adjusted) and aver-
age costs permember permonth (PMPM)were calculated overall, by demographics,
and for selected chronic conditions. Specific drug use was also examined for a
chronic condition of interest. RESULTS: Overall, the average PMPM number of fills
was 4.3 and the cost was $212, beneficiaries took 8.9 distinct medications, and
mean cost per fill was $49.75. Older beneficiaries filled more prescriptions per
month (4.9 for 85 years vs. 3.9 for 65-74 years), but had lower mean costs per fill
($46.95 for85 years vs. $51.61 for 65-74 years). Females had higher PMPM fills (4.5
vs. 3.9) and costs ($220 vs. $198) compared to males. Dual-eligible Medicare and
Medicaid beneficiaries had approximately 1.5 times higher PMPM fills and costs
compared to beneficiaries without any Part D subsidies. PMPM fills and costs also
vary with race. Compared to the overall Medicare cohort, beneficiaries with the
selected chronic conditions had higher PMPM fills and costs: diabetes (6.0, $303),
Alzheimer’s (6.0, $358), depression (6.4, $357), and osteoporosis (4.8, $261). Patterns
of use and cost by demographics differed by condition compared to the overall
cohort, except by dual eligible status. CONCLUSIONS: As demonstrated, the new
Part D LDS data allows researchers to conduct utilization and cost studies using all
and subsets of Medicare beneficiaries with selected chronic conditions.
MD3
EVALUATING THE WILLINGNESS-TO-PAY OF MEDICARE BENEFICIARIES FOR
PART D PLAN ASSISTANCE
Patel RA, Walberg MP, Na J, Hsiou D, Panchal V, Woelfel JA, Galal SM, Carr-Lopez SM,
Chan EK
University of the Pacific, Stockton, CA, USA
OBJECTIVES:Medicare Part D allows each beneficiary the ability to choose and enroll
in a privately sponsored Medicare-approved prescription drug plan (PDP). However,
with 33 different stand-alone PDPs to choose from in California in 2011 alone, such a
choice can be overwhelming. We sought to assist beneficiaries with Part D plan eval-
uation and quantify their willingness-to-pay (WTP) for such services during the 2011
open enrollment period.METHODS: Nine outreach events were held in cities across
central/northern California during which 395 beneficiaries were assisted with their
Medicare Part D plan. During each session, beneficiary-specific information (e.g.,
prescription medications) was entered into the Medicare Plan Finder Tool (www.
medicare.gov) to help facilitate the intervention. Demographic and plan-specific data,
along with the results of the intervention, were collected from each assisted benefi-
ciary. At the conclusion of the session, each beneficiary’sWTPwas elicited. RESULTS:
Of the 348 (88.1%) beneficiaries who answered the question, the median (mean) WTP
for Part D plan help was $20 ($40.04). A significant difference (p0.001) was found in
the WTP of beneficiaries as a function of whether or not they received additional
governmental assistance (e.g., Medicaid). The median (mean) WTP of 96 subsidy-re-
cipients was $0 ($12.43) versus $25 ($51.38) for 247 non-subsidy recipients. WTP was
also dependent (p0.01) on whether or not the beneficiary was enrolled into a new
plan during the interventional session. Themedian (mean)WTP of the 126 beneficia-
ries that were enrolled into a PDP plan onsite was $25 ($57.79) versus $10 ($30.00) for
the 220 beneficiaries who were not. Finally, beneficiaries’ WTP was significantly cor-
related (rs 0.235; p0.001) with the estimated annual cost savings identified during
the intervention. CONCLUSIONS: Beneficiaries valueMedicare Part D plan assistance
and the perceived value varies as a function of certain demographic and interven-
tional characteristics.
MD4
EVALUATION OF AN INTERVENTION TO REDUCE POLY-PHARMACY IN
MEDICARE PART D
Livengood KB, Harrell T, Abarca J
WellPoint, Indianapolis, IN, USA
OBJECTIVES: The objective of this study was to evaluate the relationship between
a physician-based intervention and the reduction in poly-pharmacy for a segment
of a national managed care Medicare Part D cohort.METHODS: Providers of Medi-
care Part D members in 2009 were sent a letter if one or more of their patients met
the criteria for both medication therapy management (MTM) and poly-pharmacy.
The providers were asked to review the member’s prescription profile and make
appropriate changes based solely on the provider’s clinical judgement. Two fol-
low-up quarters were defined for each member in 2009, and two baseline quarters
were defined in 2008. From prescription claims, fields were collected allowing the
creation of change variables. Changes in claim count, drug (GPI) count, and medi-
cation cost were evaluated using feasible generalized least squares and a linear
probability model (change in claim and drug count). The intervention cohort was
compared to a control cohort, consisting of Medicare Part D members who met
poly-pharmacy criteria but not MTM program criteria. RESULTS: The analysis re-
vealed a significantly greater reduction of 3.72 claims (second baseline quarter 2008
versus second follow-up quarter 2009. p  0.001) for the intervention. There was a
significantly greater reduction of 1.67 drugs (GPI8) for the intervention (p  0.001).
Medication costs for the intervention were decreased $204 (ingredient cost, $149 in
amount paid for medications, p  0.001 for both medication costs). The linear
probability model showed the intervention was associated with a 4.4%, 6.5%, and
12.9% significantly greater probability of a three to five, six to eight, and a greater
than eight, respectively, claim count reduction (p  0.001). The intervention was
also associated with a significantly greater probability of drug count reduction (p
0.001). CONCLUSIONS: The intervention was associated with a statistically signif-
icant marginal reduction in claim count, drug count, and medication costs com-




COST-EFFECTIVENESS OF DUTASTERIDE AS A CHEMOPREVENTION IN
PROSTATE CANCER: REDUCE WITHIN-TRIAL ANALYSIS
Earnshaw SR1, Chirila C1, McDade C1, Black L2, Andriole GL3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Research Triangle
Park, NC, USA, 3Washington University School of Medicine in St. Louis, St. Louis, MO, USA
OBJECTIVES: A within-trial analysis examined the cost-effectiveness of dutas-
teride as a chemoprevention comparedwith placebo, by analyzing the resource use
incurred by men in Reduction by Dutasteride of Prostate Cancer Events (REDUCE)
trial. METHODS: REDUCE was a 4-year, randomized, double-blind, placebo-con-
trolled, parallel-group trial to compare the efficacy and safety of dutasteride 0.5mg
daily with placebo for chemoprevention in men at increased risk for prostate can-
cer. Resource use datawas prospectively collected and included drugs, procedures,
outpatient visits, and inpatient visits in general and those associated with related
conditions such as hematuria, hematospermia, acute urinary retention, urinary
tract infection, benign prostatic hyperplasia, and prostate cancer. Unit costs from
standard costing sources were applied to resource use incurred during the trial.
Quality-adjusted life-years (QALYs) were calculated on the basis of men being
healthy and having BPH, prostate cancer, and adverse events. Utilities were ob-
tained from the published literature. Incremental costs per QALY were calculated.
Bootstrap analyses, to derive cost-effectiveness acceptability curves, were per-
formed. The analysis was performed from the perspective of a US health care
payer. RESULTS: Men using dutasteride incurred a mean cost of $6,610 (including
cost of dutasteride) whereas men in the placebo group incurred a mean cost of
$3,177 over the 4-year period of the trial. Men using dutasteride accrued 0.13 more
QALYs than men on placebo (3.26 vs. 3.13). As a result, the use of dutasteride as a
chemoprevention was cost-effective (incremental cost per QALY $50,000), with
an incremental cost per QALY of $26,516. The incremental cost per prostate cancer
avoided was $19. CONCLUSIONS: Using dutasteride as a chemoprevention for
prostate cancer in men at increased risk, as seen in the REDUCE trial, is cost-
effective. These cost-effective benefits of chemoprevention are realizable in a pe-
riod of time as short as 4 years.
QA2
CROSS-WALKING CANCER-SPECIFIC INSTRUMENTS TO THE EQ-5D AND SF-6D
Teckle P1, Peacock S1, van der Hoek K1, Chia S2, Melosky B2, Gelmon K2
1Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada,
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OBJECTIVES: To help facilitate economic evaluations of interventions for treating
cancer, we estimated utility indices for the two frequently used cancer-specific
(FACT-G and EORTC-QLQ-C30) instruments of quality-of-life, by mapping them
onto each of the EQ-5D and SF-6D preference-based-indices.METHODS: A sample
of 367 cancer patients from the Vancouver Cancer Centre completed four health-
related-quality-of-life questionnaires (EORTC-QLQ-C30/FACT-G/EQ-5D/SF-6D).
The sample was randomly divided to provide development(n184) and cross-vali-
dation(n183) samples. Models of the relationships between the EORTC-QLQ-C30/
FACT-G and each of the preference-based-indices were estimated using regression
analyses. We examined three alternative modeling approaches: ordinary-least-
squares(OLS); generalized-linear-modeling(GLM) using aGaussian distribution and
log-link; and censored-least-absolute deviations(CLAD). The performance of the
models was assessed in terms of how well the responses to the cancer-specific
instruments predicted utilities from each of the EQ-5D/SF-6D instruments.
RESULTS: The CLAD approach considers the non-normal(left-skew) distribution of
the utility scores and their apparent truncation at one. Results from the final mod-
els of the three approaches did not differ significantly. Physical, functional and
emotional well-being domain-scores of FACT-G significantly predict EQ-5D/SF-6D
utility scores. Physical and emotional functioning and pain subscales of the
EORTC-QLQ-C30 were significant predictors of the utility scores. Cognitive func-
tioning and insomnia subscales of the EORTC-QLQ-C-30 were significantly associ-
ated with the EQ-5D, while the social and role functioning, and fatigue were only
significant predictors of the SF-6D utility-index. The addition of age, gender, stage
of disease, and ethnicity did not lead to significant improvement in themodel. The
root mean square error(RMSE) for the SF-6D was lower (0.064), suggesting better
predictions than for the EQ-5D(0.098). CONCLUSIONS: There is potential to esti-
mate EQ-5D/SF-6D utilities using responses from the cancer-specific FACT-G/
EORTC-QLQ-C-30 measures of quality-of-life, even though the latter were not de-
signed as utility instruments. Our results suggest that it is possible to estimate
Quality-Adjusted-Life-Years(QALYs) from studies where only cancer-specific in-
struments have been administered.
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